Expert Interview
A look at the potential of sepofarsen ahead of the Illuminate trial readout in LCA10 patients
Ticker(s): PRQRInstitution: Oregon Health & Science University
- Endowed Professorship in Ophthalmology and Molecular and Medical Genetics at OHSU & chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute.
- Clinician scientist with a passion for developing novel therapeutic regimens for inherited retinal diseases.
- PI or Co-PI on numerous clinical trials including: gene augmentation therapy for: RPE65-related retinopathy, ABCA4-related retinopathy, Type IB Usher syndrome, CNGA3 and CNGB3-related achromatopsia, X-linked retinoschisis, X-linked retinitis pigmentosa, and choroideremia. In addition, he is investigator for antisense oligonucleotide therapies for: CEP290-related retinopathy, USH2A-related retinopathy, and RHO autosomal dominant retinitis pigmentosa. He is a principal investigator on the Allergan Brilliance where the first patient was treated with gene editing from CEP290-related retinopathy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
